Recent Trends in Mesothelioma Incidence in the United States

Spirtas, Robert; Beebe, Gilbert W.; Connelly, Roger R.; Wright, William E.; Peters, John; Sherwin, Russell P.; Henderson, Brian E.; Stark, Alice D.; Kovasznay, Beatrice; Davies, J. N. P.; Vianna, Nicholas J.; Keehn, Robert J.; Ortega, Louis G.; Hochholzer, Liselotte; Wagner, J. C.

doi:10.1002/ajim.4700090502

Cited by 89 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The male:female ratio has been gradually growing, reaching 2.5 in the mid-1980s (2). The incidence numbers are similar to those obtained in the United States and Great Britain in the beginning of the 1980s (4,5).…”

supporting

confidence: 71%

Relative risk of mesothelioma associated with different levels of exposure to asbestos.

Tuomi¹,

Huuskonen²,

Virtamo³

et al. 1991

Scand J Work Environ Health

View full text Add to dashboard Cite

supporting

confidence: 71%

Relative risk of mesothelioma associated with different levels of exposure to asbestos.

Tuomi¹,

Huuskonen²,

Virtamo³

et al. 1991

Scand J Work Environ Health

View full text Add to dashboard Cite

“…In Paris and suburbs [22] the incidence rate is 7.5 per million for males and 1.5 per million for females. In the USA the highest published annual rate per million is 13.3 [23,24] for males and 2.5 for females and in Australia the rates are 66 per million for males and 7 per million for females [25].…”

Section: Epidemiologymentioning

confidence: 99%

Malignant pleural mesothelioma

Boutin¹,

Schlesser²,

Frenay³

et al. 1998

Eur Respir J

171

View full text Add to dashboard Cite

The incidence of malignant pleural mesothelioma (MPM) has risen for some decades and is expected to peak between 2010 and 2020. Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. Perhaps because of this poor prognosis, early screening has incited little interest. However, certain forms may have a better prognosis when diagnosed early and treated by multimodal therapy or intrapleural immunotherapy. Diagnosis depends foremost on histological analysis of samples obtained by thoracoscopy. This procedure allows the best staging of the pleural cavity with an attempt to detect visceral pleural involvement, which is one of the most important prognostic factors. Although radiotherapy seems necessary and is efficient in preventing the malignant seeding after diagnostic procedures in patients, there has been no randomized phase III study showing the superiority of any treatment compared with another. However, for the early-stage disease (stage I) a logical therapeutic approach seems to be neoadjuvant intrapleural treatment using cytokines. For more advanced disease (stages II and III) resectability should be discussed with the thoracic surgeons and a multimodal treatment combining surgery, radiotherapy and chemotherapy should be proposed for a randomized controlled study. Palliative treatment is indicated for stage IV. In any case, each patient should be enrolled in a clinical trial.

show abstract

“…The number of cases of mesothelioma in men in creased by 12% per year between 1973 and 1980 in the United States [1] as a result of the widespread industrial use of asbestos prior to 1975. The same trend has been noted in other industrialized countries [2,3].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Sixty-Five Patients

Tammilehto

Maasilta

Kostiainen³

et al. 1992

Respiration

View full text Add to dashboard Cite

This report is an analysis of the medical records of 83 patients registered between 1960 and 1980 at Helsinki University Central Hospital as having malignant pleural mesothelioma. 65 of 83 patients had histologically confirmed malignant mesothelioma, and are the focus of this analysis. The remaining 18 (22%) patients were excluded because malignant mesothelioma was only confirmed cytologically, or because the primary tumor was not a mesothelioma. The ratio of men to women was 2:1.30 of 65 (46%) patients were not known or not likely to have been exposed to asbestos. The main symptoms at presentation were dyspnea, cough, chest pain, fatigue and weight loss. The median survival from diagnosis was 12 months, and from the onset of symptoms 18 months. Clinical stage and performance status were significant prognostic factors. Hematogenous metastases were present at autopsy in most cases. Disease and performance status therefore need to be well established and documented in clinical trials involving mesothelioma.

show abstract

Recent Trends in Mesothelioma Incidence in the United States

Cited by 89 publications

References 20 publications

Relative risk of mesothelioma associated with different levels of exposure to asbestos.

Relative risk of mesothelioma associated with different levels of exposure to asbestos.

Malignant pleural mesothelioma

Diagnosis and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Sixty-Five Patients

Contact Info

Product

Resources

About